Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
about
The expanding role of immunopharmacology: IUPHAR Review 16Update on toll-like receptor-directed therapies for human diseaseAllergy vaccines: dreams and reality.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT).Toll-like receptor modulators: a patent review (2006-2010).Prophylactic and therapeutic implications of toll-like receptor ligands.Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety.Controlled Allergen Challenge Facilities and Their Unique Contributions to Allergic Rhinitis Research.New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy.Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis.MPLA shows attenuated pro-inflammatory properties and diminished capacity to activate mast cells in comparison with LPS.Update in the mechanisms of allergen-specific immunotheraphy.A Fusion Protein Consisting of the Vaccine Adjuvant Monophosphoryl Lipid A and the Allergen Ovalbumin Boosts Allergen-Specific Th1, Th2, and Th17 Responses In Vitro.Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis.
P2860
Q26801862-EC34AF01-32E7-44F8-9B2A-4592138A790FQ36171745-FCCA4E30-40C3-48B3-BAE7-4CEB30DDFFA2Q37123463-78D04FDA-1072-4C95-9251-EA102D0D22B5Q37812128-77AE086B-2385-4483-A451-1439F44DF972Q37841682-2B90222F-EF96-4EB0-9619-3203728E4275Q37853197-87A0AA37-F5EF-4106-83A0-98BA31E5A671Q37989884-508514EB-216C-4ED0-9115-934955FE0463Q38284820-28124ABD-B712-4ED2-9704-A0308C7F5854Q38541185-508DD3F4-17AC-43E5-A713-684BDD1D0771Q38883770-C8C5B072-EE06-42E4-9F93-3685BE514C87Q40135722-596C9BC0-9ABC-42CE-8A85-195F64D45186Q41156645-16149008-15F9-4D39-96FF-1C548EFBB3DAQ41273420-4D028C5A-ECEF-4102-B79A-642856706DA2Q42713288-EE0CB402-89EF-40AE-9A56-033F6F9EDD14Q44240760-FA3CEA77-F459-4843-9EE2-E8839E0FD931
P2860
Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
@ast
Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
@en
type
label
Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
@ast
Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
@en
prefLabel
Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
@ast
Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
@en
P2860
P356
P1476
Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
@en
P2093
Anne Marie F Salapatek
Piyush Patel
P2860
P304
P356
10.1586/14760584.5.5.617
P577
2006-10-01T00:00:00Z